SAN DIEGO–(BUSINESS WIRE)–$CORT #CORT–The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Corcept Therapeutics Incorporated (NASDAQ: CORT) common stock between October 31, 2024 and December 30, 2025, both dates inclusive (the “Class Period”), have until April 21, 2026 to seek appointment as lead plaintiff of the Corcept class action lawsuit. Captioned Allegheny County Employees’ Retirement System v. Corcept Therapeutics Incorporated, No. 26-cv-01525 (N.D. Cal.), the Corcept class action lawsuit charges Corcept and certain of Corcept’s top executives with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the Corcept class action lawsuit, please provide your information here:
https://www.rgrdlaw.com/cases-corcept-therapeutics-incorporated-class-action-lawsuit-cort.html
You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected].
CASE ALLEGATIONS: Corcept engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders. One of Corcept’s lead new product candidates is relacorilant, which is being developed for multiple indications, including as a treatment for patients with hypercortisolism (also known as “Cushing’s syndrome”).
The Corcept class action lawsuit alleges that defendants throughout the Class Period represented that the relacorilant New Drug Application was supported by powerful evidence, that it was approaching approval, and that they had no concerns about the U.S. Food and Drug Administration’s (“FDA”) review. But in truth, the Corcept investor class action lawsuit alleges that the FDA had repeatedly raised concerns about the adequacy of the clinical evidence supporting the NDA and, as a result, there was a known material risk that Corcept’s relacorilant NDA would not be approved.
The Corcept shareholder class action lawsuit further alleges that on December 31, 2025 Corcept revealed that the FDA had issued a Complete Response Letter (“CRL”) regarding the NDA for relacorilant as a treatment for patients with hypercortisolism. In doing so, the press release issued by Corcept allegedly stated that the FDA had “concluded it could not arrive at a favorable benefit-risk assessment for relacorilant without Corcept providing additional evidence of effectiveness.” On this news, the price of Corcept stock fell by more than 50%.
Then, on January 30, 2026, the FDA allegedly published a redacted copy of the CRL detailing the FDA’s concerns with the relacorilant NDA, including concerns that the clinical studies that were submitted as part of the NDA were not sufficient evidence of relacorilant’s efficacy for the proposed indication. The CRL also noted that, during pre-submission meetings, the FDA informed Corcept “on several occasions” of its “concerns about the adequacy of the clinical development program,” and had warned the Company “to expect significant review issues,” if it submitted the application, the Corcept class action alleges.
THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Corcept common stock during the Class Period to seek appointment as lead plaintiff in the Corcept class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Corcept investor class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Corcept shareholder class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Corcept class action lawsuit.
ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:
https://www.rgrdlaw.com/services-litigation-securities-fraud.html
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Contacts
Robbins Geller Rudman & Dowd LLP
J.C. Sanchez
655 W. Broadway, Suite 1900, San Diego, CA 92101
800-449-4900
[email protected]
